The use of peptide analogs for the therapy of various cancers is reviewed. Inhibition of the
pituitary–gonadal axis forms the basis for oncological applications of luteinizing hormone …

This article reviews the potential clinical uses of antagonists of growth-hormone-releasing
hormone (GHRH) for tumor therapy. GHRH antagonists suppress the growth of various …

The family of GH secretagogues (GHS) includes synthetic peptidyl (hexarelin) and
nonpeptidyl (MK-0677) molecules possessing specific receptors in the pituitary and central …

There is abundant in vitro, animal and epidemiologic evidence to suggest that the Insulin-
Like Growth Factor (IGF) family is a multi-component network of molecules which is involved …

The proliferation of various tumors is inhibited by the antagonists of growth hormone-
releasing hormone (GHRH) in vitro and in vivo, but the receptors mediating the effects of …

The growth hormone–insulin-like growth factor-I (GH–IGF-I) axis plays a fundamental role in
the development of the breast. The maintenance of breast tissue architecture is aided by its …

In this article, we briefly review the identification of GHRH, provide an abridged overview of
GHRH antagonists, and focus on studies with GHRH agonists. Potent GHRH agonists of JI …

Ghrelin is a recently identified 28 amino acid peptide capable of stimulating pituitary growth
hormone release in humans. The actions of ghrelin are mediated via the naturally occurring …

Various attempts to detect human pituitary growth hormone-releasing hormone receptor
(pGHRH-R) in neoplastic extrapituitary tissues have thus far failed. Recently, four splice …

Post-translational modification of proteins is an important regulatory event. Numerous
biologically active peptides that play an essential role in cancerogenesis contain an …